The research for the urinary RANTES・MCP-1 as the urine tumor markers for bladder cancer

尿液RANTES・MCP-1作为膀胱癌尿液肿瘤标志物的研究

• 批准号: 22791465
• 负责人: TSURUTA Hiroshi
• 金额: $ 1.75万
• 依托单位: Akita University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Young Scientists (B)
• 财政年份: 2010
• 资助国家: 日本
• 起止时间: 2010 至 2011
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-22791465/
• 关键词: 腫瘍学; 膀胱癌; RANTES; CCR5; 尿中サイトカイン

We measured the urinary cytokines using ELISA, and found that mean urinary RANTES level were significantly higher than that of healthy control. Immunohistologically, the expression of CCR5, which is main receptor of RANTES, was found in primary bladder tumors. There was a statistically significant association between increased CCR5 expression in tumors and tumor stage or tumor grade. The high grade or high stage tumors had significantly higher expression levels of CCR5.Our results suggest that the high level of urine RANTES may be a candidate novel marker of the presence of bladder cancer. Furthermore, the increased CCR5 expression in the cytoplasm of bladder cancer cells may be associated with aggressive type of bladder cancer and be a marker for disease progression.

采用ELISA法检测尿中细胞因子水平，发现尿RANTES水平明显高于健康对照组。免疫组织学检查发现，RANTES的主要受体CCR 5在原发性膀胱肿瘤中有表达。肿瘤中CCR5表达增加与肿瘤分期或肿瘤分级之间存在统计学显著相关性。高级别或高分期膀胱癌中CCR5的表达水平明显增高。本研究结果提示，尿RANTES的高水平可能是膀胱癌的一个新的候选标志物。此外，CCR5在膀胱癌细胞胞质中的表达增加可能与膀胱癌的侵袭性类型相关，并且是疾病进展的标志物。

项目成果

尿路上皮癌に対する Gemcitabine-Carboplatin-Docetaxel(GCD)療法の治療成績

吉西他滨-卡铂-多西他赛（GCD）治疗尿路上皮癌的治疗结果

• 发表时间: 2009
• 作者: 苗村潔;齋藤英也;鶴田大(筆頭);鶴田大(筆頭);鶴田大(筆頭)
• 通讯作者: 鶴田大(筆頭)

Elevated urinary levels of RANTES and high expression levels of the RANTES receptor (CCR5) in bladder cancer

膀胱癌中尿 RANTES 水平升高和 RANTES 受体 (CCR5) 表达水平高

• 发表时间: 2011
• 作者: 鶴田大;堀川洋平;成田伸太郎;井上高光;小原崇;沼倉一幸;佐藤滋;土谷順彦;羽渕友則
• 通讯作者: 羽渕友則

Combination therapy consisting of gemcitabine, carboplatin, and docetaxel as an active treatment for advanced urothelial carcinoma

• DOI: 10.1007/s10147-011-0224-4
• 发表时间: 2011-03
• 期刊: International Journal of Clinical Oncology
• 影响因子: 3.3
• 作者: H. Tsuruta;T. Inoue;S. Narita;Y. Horikawa;M. Saito*;T. Obara;K. Numakura;S. Maita;S. Satoh

Combination therapy consisting of gemcitabine, carboplatin, and docetaxel (GCD) as an active treatment for advanced urothelial cell carcinoma

由吉西他滨、卡铂和多西他赛 (GCD) 组成的联合疗法作为晚期尿路上皮细胞癌的积极治疗方法

• 发表时间: 2010
• 作者: 鶴田大;堀川洋平;成田伸太郎;井上高光;小原崇;沼倉一幸;佐藤滋;土谷順彦;羽渕友則;Yamada S;鶴田大;Yamada S;鶴田大
• 通讯作者: 鶴田大

膀胱癌におけるRANTES多型の検討

膀胱癌RANTES多态性检测

• 发表时间: 2009
• 作者: 鶴田大;成田伸太郎;堀川洋平;熊澤光明;斉藤満;湯浅健;佐藤滋;土谷順彦;羽渕友則
• 通讯作者: 羽渕友則